ibrutinib
abbvie,janssen
['leukemia', ' ibru']
pharma study finds their drug has 'more compliance' than competitor drug. #ash22 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????